Strategic Initiative

Slingshot members are tracking this corporate initiative:

Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases for $1.2B

Source Link:: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2153767

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

Community voting in process

Nimbus Therapeutics

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Apr 04, 2016

Projected Implementation:

Q1, 2016

Relevance Tracked Until:

Q2, 2016

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Acetyl-coa Carboxlyase, Acc, Nash, Liver Diseases, Ndi-010976, Fast Track Designation, Metabolic Dysfunction, Hepatocellular Injury, Acc Inhibitors, Aberrant Lipid-derived Signaling, Steatosis, Fibrosis, Inflammation